Περίληψη:
The outbreak of the SARS-CoV-2-induced coronavirus disease 2019 (COVID-19) pandemic re-shaped doctor-patient interaction and challenged capacities of healthcare systems. It created many issues around the optimal and safest way to treat complex patients with severe allergic disease. A significant number of the patients are on treatment with biologicals, and clinicians face the challenge to provide optimal care during the pandemic. Uncertainty of the potential risks for these patients is related to the fact that the exact sequence of immunological events during SARS-CoV-2 is not known. Severe COVID-19 patients may experience a “cytokine storm” and associated organ damage characterized by an exaggerated release of pro-inflammatory type 1 and type 3 cytokines. These inflammatory responses are potentially counteracted by anti-inflammatory cytokines and type 2 responses. This expert-based EAACI statement aims to provide guidance on the application of biologicals targeting type 2 inflammation in patients with allergic disease. Currently, there is very little evidence for an enhanced risk of patients with allergic diseases to develop severe COVID-19. Studies focusing on severe allergic phenotypes are lacking. At present, noninfected patients on biologicals for the treatment of asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, or chronic spontaneous urticaria should continue their biologicals targeting type 2 inflammation via self-application. In case of an active SARS-CoV-2 infection, biological treatment needs to be stopped until clinical recovery and SARS-CoV-2 negativity is established and treatment with biologicals should be re-initiated. Maintenance of add-on therapy and a constant assessment of disease control, apart from acute management, are demanded. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Συγγραφείς:
Vultaggio, A.
Agache, I.
Akdis, C.A.
Akdis, M.
Bavbek, S.
Bossios, A.
Bousquet, J.
Boyman, O.
Chaker, A.M.
Chan, S.
Chatzipetrou, A.
Feleszko, W.
Firinu, D.
Jutel, M.
Kauppi, P.
Klimek, L.
Kolios, A.
Kothari, A.
Kowalski, M.L.
Matucci, A.
Palomares, O.
Pfaar, O.
Rogala, B.
Untersmayr, E.
Eiwegger, T.
Λέξεις-κλειδιά:
benralizumab; cyclosporine; dupilumab; immunoglobulin E antibody; interleukin 4 receptor; interleukin 5; interleukin 5 receptor; mepolizumab; omalizumab; reslizumab; biological product, adaptive immunity; allergic asthma; allergic disease; antiinflammatory activity; Article; asthma; atopic dermatitis; chronic rhinosinusitis; chronic urticaria; clinical feature; clinical practice; clinical trial (topic); coronavirus disease 2019; cytokine storm; disease association; disease control; human; immune response; inflammation; managed care; meta analysis (topic); nose polyp; pandemic; patient risk; phase 3 clinical trial (topic); phenotypic variation; practice guideline; priority journal; risk assessment; risk factor; Severe acute respiratory syndrome coronavirus 2; treatment indication; complication; Europe; hypersensitivity; immunology; organization, Academies and Institutes; Biological Products; COVID-19; Europe; Humans; Hypersensitivity; Pandemics
